Showing results (521-530 of 567) with videos related to

Sort By:
Pageof 57
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
Hypertension (Dallas, Tex. : 1979)|December 5, 2025
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled TrialVikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
European Urology|September 15, 2023
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before MaintenanceSrikala S Sridhar, Thomas Powles, Miguel Á Climent Durán, et al.
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Urologic Oncology|July 29, 2014
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forwardAndrea B Apolo, Vanessa Hoffman, Matthew G Kaag, et al.
Cancer Medicine|May 18, 2016
High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancersKrisha Desai, Madhumathy G Nair, Jyothi S Prabhu, et al.
Pageof 57